IMiDs mediate anti‐MM effects by binding to the E3 ubiquitin ligase cereblon (CRBN) [1, 2, 3], which subsequently increases degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), culminating in downregulation of IRF4 and MYC expression leading to inhibition of MM cell growth [4, 5]. This evidence concerns the gene IKZF3 and Miyoshi myopathy.